Table 3:
Qualitative assessment of patients with brain tumors: intraindividual comparison of 0.05-mmol/kg gadobenate and 0.1-mmol/kg gadoteratea
| Diagnostic Information End Point | Reader | Gadobenate Preferred | No Difference | Gadoterate Preferred | Significance (P Value)b | 3-Reader Agreement κ Value (% Agreement) |
|---|---|---|---|---|---|---|
| Global diagnostic preference | 1 | 14 (14.6%) | 75 (78.1%) | 7 (7.3%) | .13 | 0.505 (63.4%) |
| 2 | 18 (19.2%) | 56 (59.6%) | 20 (21.3%) | .75 | ||
| 3 | 15 (15.8%) | 63 (66.3%) | 17 (17.9%) | .73 | ||
| Lesion-border delineation | 1 | 11 (11.4%) | 76 (79.2%) | 9 (9.4%) | .824 | 0.493 (71.0%) |
| 2 | 12 (12.8%) | 66 (70.2%) | 16 (17.0%) | .46 | ||
| 3 | 8 (8.4%) | 77 (81.1%) | 10 (10.5%) | .815 | ||
| Definition of disease extent | 1 | 6 (6.3%) | 84 (87.5%) | 6 (6.3%) | 1.00 | 0.443 (79.6%) |
| 2 | 5 (5.3%) | 83 (88.3%) | 6 (6.4%) | 1.00 | ||
| 3 | 7 (7.4%) | 80 (84.2%) | 8 (8.4%) | 1.00 | ||
| Visualization of lesion internal morphology | 1 | 4 (4.2%) | 88 (91.7%) | 4 (4.2%) | 1.00 | 0.459 (84.9%) |
| 2 | 3 (3.2%) | 87 (92.6%) | 4 (4.3%) | 1.00 | ||
| 3 | 5 (5.3%) | 82 (86.3%) | 8 (8.4%) | .581 | ||
| Lesion contrast enhancement | 1 | 10 (10.4%) | 77 (80.2%) | 9 (9.4%) | 1.00 | 0.531 (66.7%) |
| 2 | 18 (19.2%) | 56 (59.6%) | 20 (21.3%) | .75 | ||
| 3 | 14 (14.7%) | 64 (67.4%) | 17 (17.9%) | .598 |
a
Comparisons based on the number of patients with both postdose T1SE images assessed and technically adequate: n = 96 for reader 1, n = 94 for reader 2, and n = 95 for reader 3. Numbers in parentheses, except where noted, represent proportions of patients.
b
Wilcoxon signed rank test.